Mod GRF, Ipamorelin 10mg (Blend)
$95.00
PRODUCT SHORT DESCRIPTION
The Mod GRF & Ipamorelin research blend combines two highly selective growth hormone secretagogues to model dual-receptor regulation within the somatotropic axis. This 10mg formulation provides a precise biochemical tool for investigating synchronized growth hormone pulsatility and receptor signaling crosstalk without secondary endocrine disruption.
Introduction to the Mod GRF & Ipamorelin Blend
The Mod GRF & Ipamorelin Blend 10mg represents a highly refined, multi-component peptide matrix engineered for high-resolution studies in endocrinology, cellular signaling, and somatotropic axis regulation. By pairing a stabilized Growth Hormone-Releasing Hormone (GHRH) analog with Ipamorelin—a highly selective agonist of the Growth Hormone Secretagogue Receptor (GHSR)—this formulation functions as a comprehensive, dual-pathway research model. At USA PEPTIDE SCIENCES, we supply this advanced secretagogue blend as a single, uniform 10mg lyophilized cake. This integrated presentation offers research laboratories an optimized, synergistic platform to examine synchronized cellular degranulation, receptor-ligand kinetics, and competitive neuroendocrine feedback loops without compounding weighing variables.
Research Overview: Dual-Pathway Receptor Signaling Crosstalk
The primary investigative utility of this dual-peptide blend centers on its ability to mimic and maximize natural growth hormone (GH) pulse amplitudes by simultaneously targeting separate regulatory mechanisms in pituitary somatotrophs.
Key areas of active scientific investigation utilizing this blend include:
-
Synergistic Pituitary Activation Dynamics: Modeling how the concurrent activation of GHRH receptors (by Mod GRF) and GHSR/ghrelin receptors (by Ipamorelin) creates a compounding intracellular signaling cascade via cyclic adenosine monophosphate (cAMP) and phospholipase C (PLC) pathways.
-
Somatostatin Inhibition Kinetics: Investigating the capacity of the ghrelin receptor agonist to down-regulate the inhibitory influence of somatostatin (growth hormone-inhibiting hormone), thereby extending the duration of simulated secretory phases.
-
Receptor Selectivity and Endocrine Baselines: Evaluating the structural properties of Ipamorelin, which selectively drives growth hormone release from pituitary somatotrophs without triggering secondary cascades that elevate adrenocorticotropic hormone (ACTH), cortisol, or prolactin expression in vitro.
-
Pulsatility Profile Mapping: Tracking the pharmacokinetic curve, metabolic clearance, and pulse frequency modifications of the combined molecules compared to isolated single-peptide controls over extended trial timelines.
Composition and Quality Validation of the Peptide Matrix
To support rigorous, repeatable analytical trials, each constituent peptide in the blend is synthesized to exact structural specifications before integration:
-
Mod GRF (Modified GRF 1-29 / CJC-1295 No DAC): A 29-amino-acid tetrasubstituted peptide analog optimized for structural stability against rapid blood plasma dipeptidyl peptidase-4 (DPP-4) cleavage.
-
Ipamorelin: A highly selective pentapeptide ($\text{Aib-His-D-2-Nal-D-Phe-Lys-NH}_2$) known for initiating robust growth hormone release while maintaining natural baseline levels of other anterior pituitary hormones.
At USA PEPTIDE SCIENCES, operational accuracy and total chemical fidelity are our core manufacturing principles. Every single lot of our combined secretagogue matrix undergoes rigorous High-Performance Liquid Chromatography (HPLC) coupled with Mass Spectrometry (MS) to confirm an absolute chemical purity profile of 99% or greater for each independent sequence. A batch-specific Certificate of Analysis (COA) is issued with every order to ensure absolute experimental continuity.
Storage and Handling Requirements
To preserve the complex molecular bonds and prevent structural degradation of the Mod GRF & Ipamorelin Blend, the vacuum-sealed, lyophilized powder must be stored long-term in a freezer environment at -20°C. Prior to introducing the compound into your laboratory workflow, reconstitution must be carried out using an appropriate sterile, non-pyrogenic, or bacteriostatic diluent. Once transitioned into a liquid state, the combined peptide matrix is highly sensitive to thermal breakdown and mechanical stress; reconstituted vials must be maintained under constant refrigeration at 2°C to 8°C. Researchers must dissolve the compound via a slow, gentle swirling motion, avoiding any aggressive mechanical agitation or shaking.
Research Use Disclaimer
The compounds distributed by USA PEPTIDE SCIENCES, including the Mod GRF & Ipamorelin Blend, are designated strictly for laboratory research purposes only. Under no circumstances are these products approved or intended for human or veterinary consumption, direct clinical diagnostics, or therapeutic drug administration. All handling, measuring, and experimental evaluation must be conducted exclusively by qualified scientific professionals within a certified and monitored research facility.

Reviews
Clear filtersThere are no reviews yet.